Pictura Bio Ltd

Overview

Legal name

PICTURA BIO LTD

Region

Yorkshire and the Humber

Registered address

35 WESTGATE

HUDDERSFIELD

WEST YORKSHIRE

HD1 1PA

Insolvency history

Corporate ownership

Updated 06 Jun 2026 16:52

Controls 2

Pictura Bio Ltd

No active corporate controller recorded.

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS

Turnover

Unknown

Profit / Loss

Unknown

Employees

Company events

Reference milestones and recent Companies House filing stream events.

9 events

30 Sep

2027

Accounts due

Accounts Due

Next accounts due date

02 Nov

2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec

2025

Accounts filed

Accounts

Last accounts made up date

19 Oct

2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

21 Nov

2024

Default Companies House Registered Office Address Applied

Address

RP05 | Transaction MzQ0NDQzNTkxOWFkaXF6a2N4 | Paper/PDF filed

Published 22 Nov 2024 03:13

28 Oct

2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0MTA0NzQwMGFkaXF6a2N4

Published 28 Oct 2024 03:28

19 Aug

2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzMjYxNjk1MGFkaXF6a2N4

Published 19 Aug 2024 11:47

10 Aug

2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzMTc4NjM0NWFkaXF6a2N4

Published 10 Aug 2024 14:36

20 Oct

2021

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards

First funded

2022

Funded years

2022, 2023

Age at first award

0 years

Projects

2023 Collaborative R&D Lead participant

Pictura Bio: Machine learning enhanced universal point of care diagnosis platform for infectious diseases leveraging novel fluorescent labelling of enveloped pathogens - developing the Alpha Prototype.

1 Oct 2023 to 30 Jun 2025

Awarded

£672,153

Total cost £960,219

UK-based start-up PicturaBio Ltd will transform existing approaches to human virus detection, through the development of an infectious disease diagnosis platform, leveraging PicturaBio's unique pathogen identification technology, IRIS, for "facial recognition of pathogens". Infectious diseases caused by pathogens like influenza, parainfluenza, and respira...

2022 Collaborative R&D Lead participant

OxDX: Machine learning enhanced point of care diagnosis platform for infectious diseases: faster, more accessible, user intuitive, leveraging novel fluorescent labelling of enveloped viruses.

1 Sep 2022 to 31 Aug 2023

Awarded

£287,141

Total cost £410,201

UK-based start-up OxDX Ltd will transform existing approaches to human virus detection, through the development of an infectious disease diagnosis platform, leveraging OxDX's unique pathogen identification technology. Infectious diseases caused by pathogens like influenza, parainfluenza and respiratory syncytial virus cause many thousands of deaths annual...

Product types

Collaborative R&D